Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - July 2014


Biochemical Assays for Screening Workshop

09 Jul 2014 - 11 Jul 2014 - Hamburg, Germany



Bookmark and Share


Taking place over three days at the European ScreeningPort facility in Hamburg, the workshop will offer attendees the chance to participate in practical sessions using the latest technology available from the top screening equipment / reagent vendors in the pharmaceutical industry.

This is a must-attend event for anyone in the drug discovery industry to learn about screening technologies and discover what they can do for your company or laboratory.

Who should attend

• Scientists at all levels (undergraduates, postgraduates and laboratory based scientists within academic and industrial research organisations) who are engaged in early stage drug discovery and have an interest in the development, validation and utilisation of biochemical assays for screening against small molecule libraries.

• The course will include a series of lectures describing the screening compatible biochemical assays for use in drug discovery.

• The majority of the course will be laboratory based in which assays for targets that are currently actively being pursued for drug discovery purposes (kinases, histone deacetylases and proteases) will be developed, validated and screened against a small molecule library (known drugs). Selected Hit compounds will be evaluated in suitable Secondary assays.

Expected outcomes from the workshop

It is envisaged that upon completion of the course, attendees will have gained an insight into the key parameters to be considered when developing biochemical assays and performing small molecule screening, data analysis and validation of Hits in suitable Secondary assays.

Agenda Topics

•    Km Determination for Substrates
•    Aspects of Adaption of Assays for Screening of a Small Molecule Library (Known Drugs)
•    Choice of Biochemical Assay Development Projects: Kinase, Protease or Histone Deacetylase
•    Data Analysis and Classifying Compounds as Hits
•    IC50 Determination for Inhibitor, Signal Stability, Choice of Liquid Handling and Z’
•    Interferers
•    Kinetic Characterisation of Enzymes
•    Validation of Hits Selected from Screening Campaigns



Further information
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!